Suicide Risk Factors in Patients with Genitourinary Malignancies
the Cancer Therapy Advisor take:
Patients with genitourinary tumors, especially men, the elderly, and those with aggressive disease, are exposed to an increased number of suicide risk factors, according to an article published online in Cancer.
The study identified patients with prostate, bladder, kidney, testis, and penile cancer through the Surveillance, Epidemiology, and End Results database (1988-2012). Odd ratios (ORs) were also calculated to determine associated suicide factors for each type of cancer.
Out of the 1,239,522 patients with genitourinary malignancies, 2,268 suicides were noted. The calculated standardized mortality ratio (SMR) for patients was 1.37 for prostate cancer (0.99-1.86), 2.71 for bladder cancer (2.02-3.62), 1.86 for kidney cancer (1.32-2.62), 1.23 for testis cancer (0.88-1.73), and 0.95 for penile cancer (0.65-1.35), each with a 95% confidence interval.
ORs were calculated for the association of male sex and suicide risk for patients with bladder and kidney cancer (6.63 and 4.98, respectively). For elderly patients with prostate, bladder, and testis cancer, their increasing age was also associated with suicide (OR range, 1.03-1.06).
The researchers concluded that African American patients with prostate, bladder, and kidney cancer were less likely to commit suicide than their male counterparts (OR range, 0.26-0.46).
The study suggests that clinicians be increasingly aware of the suicide risk in patients with genitourinary malignancies.
Patients with genitourinary tumors are exposed to an increased number of suicide risk factors.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma